Vaccination against vimentin resulted in reduced tumor growth explained by the induction of a robust vimentin-specific humoral response, altered expression of leukocyte adhesion molecules, and a notable switch in the intratumoral immune cell repertoire. The gene discussed is VIM; the disease is neoplasm.